Cubist Pharmaceuticals (NASDAQ:CBST) had its price objective hosited by Jefferies Group from $76.00 to $82.00 in a report released on Tuesday, American Banking & Market News reports.
Cubist Pharmaceuticals (NASDAQ:CBST) traded down 0.17% on Tuesday, hitting $68.64. 242,319 shares of the company’s stock traded hands. Cubist Pharmaceuticals has a 1-year low of $38.86 and a 1-year high of $72.64. The stock has a 50-day moving average of $64.11 and a 200-day moving average of $59.32. The company has a market cap of $5.083 billion and a price-to-earnings ratio of 178.60. Cubist Pharmaceuticals also was the recipient of unusually large options trading activity on Monday. Traders bought 22,840 put options on the stock. This represents an increase of approximately 942% compared to the average daily volume of 2,192 put options.
Cubist Pharmaceuticals (NASDAQ:CBST) last released its earnings data on Thursday, October 17th. The company reported $0.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.07. The company had revenue of $266.00 million for the quarter, compared to the consensus estimate of $267.96 million. During the same quarter in the prior year, the company posted $0.55 earnings per share. The company’s quarterly revenue was up 11.7% on a year-over-year basis. On average, analysts predict that Cubist Pharmaceuticals will post $-0.11 earnings per share for the current fiscal year.
CBST has been the subject of a number of other recent research reports. Analysts at Morgan Stanley initiated coverage on shares of Cubist Pharmaceuticals in a research note to investors on Wednesday, November 13th. They set an overweight rating and a $85.00 price target on the stock. Separately, analysts at Thomson Reuters/Verus downgraded shares of Cubist Pharmaceuticals from a hold rating to a sell rating in a research note to investors on Monday, October 28th. Finally, analysts at Cantor Fitzgerald cut their price target on shares of Cubist Pharmaceuticals from $72.00 to $63.00 in a research note to investors on Thursday, October 24th. They now have a hold rating on the stock. One research analyst has rated the stock with a sell rating, six have given a hold rating and seven have assigned a buy rating to the company. The stock currently has an average rating of Hold and an average target price of $66.71.
Cubist Pharmaceuticals, Inc (NASDAQ:CBST) is a biopharmaceutical company focused on the research, development and commercialization of therapies to treat serious medical conditions in acutely ill patients who are hospitalized or are being treated in other acute care settings.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.